Claudin-4 Protein-VLP, Human, Recombinant

Claudin-4 (CLDN4) is a key component of tight junctions (TJs) in epithelial cells. CLDN4 is overexpressed in many epithelial malignancies and correlates with cancer progression. Changes in CLDN4 expression have been associated with epigenetic factors (such as hypomethylation of promoter DNA), inflammation associated with infection and cytokines, and growth factor signaling. CLDN4 helps to maintain the tumor microenvironment by forming TJs and acts as a barrier to the entry of anticancer drugs into tumors.

规格	价格/CNY		数量
100 μg	￥ 10,300	5日内发货
500 μg	￥ 41,500	5日内发货
1 mg	￥ 69,200	5日内发货

规格

价格/CNY

货期

数量

100 μg

￥ 10,300

5日内发货

500 μg

￥ 41,500

5日内发货

1 mg

￥ 69,200

5日内发货

生物活性

Immobilized Human Claudin 4 VLP at 1μg/ml (100μl/well) on the plate. Dose response curve for Anti-Claudin 4 Antibody, hFc Tag with the EC50 of 18.4ng/ml determined by ELISA.

产品描述

种属	Human
表达系统	HEK293 Cells
蛋白编号	O14493
别名	Claudin4, CLDN4, Claudin-4, CPETR1, CPE-R, WBSCR8, CPE R
蛋白构建	Met1-Val209
蛋白纯度	> 95% as determined by HPLC
分子量	23.31 kDa (predicted)

内毒素	< 1 EU/μg by the LAL method.
缓冲液	Supplied as 0.22 μm filtered solution in PBS (pH 7.4).Notice: If you need it for immunization, Do Not use any adjuvant.
存储	It is recommended to store the product under sterile conditions at -70°C or lower. Samples are stable for up to 12 months at -80°C. Please avoid multiple freeze-thaw cycles and store products in aliquots.
运输方式	In general, Lyophilized powders are shipping with blue ice. Solutions are shipping with dry ice.
研究背景	Claudin-4 (CLDN4) is a key component of tight junctions (TJs) in epithelial cells. CLDN4 is overexpressed in many epithelial malignancies and correlates with cancer progression. Changes in CLDN4 expression have been associated with epigenetic factors (such as hypomethylation of promoter DNA), inflammation associated with infection and cytokines, and growth factor signaling. CLDN4 helps to maintain the tumor microenvironment by forming TJs and acts as a barrier to the entry of anticancer drugs into tumors.